Relay Therapeutics (RLAY) Current Deferred Revenue (2021 - 2024)

Relay Therapeutics (RLAY) has 4 years of Current Deferred Revenue data on file, last reported at $7.7 million in Q4 2024.

• Current Deferred Revenue for Q4 2024 came in at $7.7 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $7.7 million (changed N/A YoY), and the FY2024 annual result was $7.7 million, changed N/A from the prior year.
• Current Deferred Revenue grew to $7.7 million in Q4 2024 per RLAY's latest filing, from $24000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $7.7 million in Q4 2024 and troughed at $15000.0 in Q2 2023.
• A 4-year average of $1.1 million and a median of $207000.0 in 2021 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue plunged 79.95% in 2022, then sank 81.93% in 2023.
• A 4-year view of Current Deferred Revenue shows it stood at $248000.0 in 2021, then tumbled by 66.53% to $83000.0 in 2022, then slumped by 71.08% to $24000.0 in 2023, then soared by 31895.83% to $7.7 million in 2024.
• Business Quant data shows RLAY's Current Deferred Revenue at $7.7 million in Q4 2024, $24000.0 in Q3 2023, and $15000.0 in Q2 2023.